"id_redcap","id_covidence","study_label","article","virus","population","outcome","study_design","rob","adjusted","estimate","lower","upper","country","us","study_setting","study_period","year_start","year_end","vax_product","age_group","days_since_vax","published_year","journal","pmid","pmcid","doi","link","title"
101,"#19017","Tartof 2024","Tartof 2024","COVID","Adult/Elder","Hospitalization","Case-control","Low",1,57,45,66,"US",1,"Kaiser Permanente Southern California","2023-2024",2023,2024,"BNT162b2_XBB.1.5",,,2024,"JAMA Netw Open",39666343,"PMC11638790","10.1001/jamanetworkopen.2024.49944","https://pmc.ncbi.nlm.nih.gov/articles/PMC11638790","BNT162b2 XBB Vaccine for COVID-19 Among Children 5-17 Years of Age"
405,"#2106","Levy 2025","Levy 2025","COVID","Adult/Elder","Hospitalization","Case-control","High",1,52,34,64,"US",1,"Multi-center","2023-2024",2023,2024,"mRNA XBB1.5 booster",,,2025,"Front Immunol",40034704,"PMC11872700","10.3389/fimmu.2025.1470609","https://pmc.ncbi.nlm.nih.gov/articles/PMC11872700","XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants"
227,"#5200","Caffrey 2024","Caffrey 2024","COVID","Adult/Elder","Hospitalization","Case-control","Low",1,43,34,51,"US",1,"Nationwide (VAMC)","2023-2024",2023,2024,"BNT162b2_XBB.1.5",,,2024,"Nat Commun",39488521,"PMC11531596","10.1038/s41467-024-53842-w","https://pmc.ncbi.nlm.nih.gov/articles/PMC11531596","Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System"
470,"#23468","Nguyen 2025","Nguyen 2025","COVID","Adult/Elder","Hospitalization","Case-control","Low",1,54,38,65,"Belgium, Germany, Italy, Spain",0,"Multi-center","2023-2024",2023,2024,"BNT162b2_XBB.1.5",,,2025,"EClinicalMedicine",39726669,"PMC11669791","10.1016/j.eclinm.2024.102995","https://pmc.ncbi.nlm.nih.gov/articles/PMC11669791","Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform"
189,"#202","Andersen 2025","Andersen 2025","COVID","Adult/Elder","Hospitalization","Cohort","Low",1,36,18,50,"US",1,"Multi-center","2023-2024",2023,2024,"mRNA XBB1.5",,,2025,"Vaccine",39987879,,"10.1016/j.vaccine.2025.126881","https://pubmed.ncbi.nlm.nih.gov/39987879","Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states"
587,"#40038","Wilson 2025","Wilson 2025","COVID","Adult/Elder","Hospitalization","Cohort","Low",1,51,48,54,"US",1,"Multi-center","2023-2024",2023,2024,"mRNA XBB1.5",,,2025,"Infect Dis Ther",39708059,,"10.1101/2025.03.27.25324770v1","https://pubmed.ncbi.nlm.nih.gov/39708059","Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Associated Hospitalizations and Medically Attended COVID-19 among adults aged  18 years in the United States"
252,"#5494","Chong 2024","Chong 2024","COVID","Adult/Elder","Hospitalization","Cohort","Low",1,42,9,63,"Singapore",0,"Nationwide","2023-2024",2023,2024,"mRNA XBB1.5",,,2024,"Clin Infect Dis",38922669,,"10.1093/cid/ciae339","https://pubmed.ncbi.nlm.nih.gov/38922669","Risks of SARS-CoV-2 JN.1 Infection and COVID-19-Associated Emergency Department Visits/Hospitalizations Following Updated Boosters and Prior Infection: A Population-Based Cohort Study"
190,"#13126","Andersson 2024","Andersson 2024","COVID","Elder","Hospitalization","Cohort","Low",1,57.9,49.9,65.8,"Denmark, Sweden, Finland",0,"Multi-center","2023-2024",2023,2024,"mRNA XBB1.5",,,2024,"BMJ Med",39902239,"PMC11789462","10.1136/bmjmed-2024-001074","https://pmc.ncbi.nlm.nih.gov/articles/PMC11789462","Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data"
587,"#40038","Wilson 2025","Wilson 2025","COVID","Elder","Hospitalization","Cohort","Low",1,56,51,61,"US",1,"Multi-center","2023-2024",2023,2024,"mRNA XBB1.5",,,2025,"Infect Dis Ther",39708059,,"10.1101/2025.03.27.25324770v1","https://pubmed.ncbi.nlm.nih.gov/39708059","Evaluating the Effectiveness of 2024-2025 Seasonal mRNA-1273 Vaccination Against COVID-19-Associated Hospitalizations and Medically Attended COVID-19 among adults aged  18 years in the United States"
189,"#202","Andersen 2025","Andersen 2025","COVID","Elder","Hospitalization","Cohort","Low",1,47,28,61,"US",1,"Multi-center","2023-2024",2023,2024,"mRNA XBB1.5",,,2025,"Vaccine",39987879,,"10.1016/j.vaccine.2025.126881","https://pubmed.ncbi.nlm.nih.gov/39987879","Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states"
227,"#5200","Caffrey 2024","Caffrey 2024","COVID","Immunocompromised","Hospitalization","Case-control","Low",1,33,16,47,"US",1,"Nationwide (VAMC)","2023-2024",2023,2024,"BNT162b2 XBB","≥18y","15-133 d",2024,"Nat Commun",39488521,"PMC11531596","10.1038/s41467-024-53842-w","https://pmc.ncbi.nlm.nih.gov/articles/PMC11531596","Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System"
413,"#8103","Link-Gelles 2024","Link-Gelles 2024","COVID","Immunocompromised","Hospitalization","Case-control","Low",1,36,25,46,"US",1,"VISION network","2023-2024",2023,2024,"XBB.1.5 monovalent","≥18y","7-119 d",2024,"MMWR Morb Mortal Wkly Rep",38547037,"PMC10986819","10.15585/mmwr.mm7312a5","https://pmc.ncbi.nlm.nih.gov/articles/PMC10986819","Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged 18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024"
415,"#2182","Link-Gelles 2025","Link-Gelles 2025","COVID","Immunocompromised","Hospitalization","Case-control","Low",1,40,21,54,"US",1,"Multi-center","2024-2025",2024,2025,"Multiple","≥65y","7-119 d",2025,"MMWR Morb Mortal Wkly Rep",40014628,"PMC11867580","10.15585/mmwr.mm7406a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867580","Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged 18 Years - VISION and IVY Networks, September 2024-January 2025"
470,"#23468","Nguyen 2025","Nguyen 2025","COVID","Immunocompromised","Hospitalization","Case-control","Low",1,56,22.5,75,"Belgium, Germany, Italy, Spain",0,"Multi-center","2023-2024",2023,2024,"BNT162b2_XBB.1.5","≥18y","14-151 d",2025,"EClinicalMedicine",39726669,"PMC11669791","10.1016/j.eclinm.2024.102995","https://pmc.ncbi.nlm.nih.gov/articles/PMC11669791","Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform"
629,"#39029","Williams 2025","Williams 2025","RSV","Pregnancy","Hospitalization","Case-control","Low",1,58,28,75,"England",0,"Multi-center","2024-2025",2024,2025,"RSVPreF",,,2025,"Lancet Child Adolesc Health",40690922,,"10.1016/s2352-4642(25)00155-5","https://pubmed.ncbi.nlm.nih.gov/40690922","Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study"
5,"#21721","Gentile 2025","Gentile 2025","RSV","Pregnancy","Hospitalization","Case-control","Low",1,78.7,51.4,90.7,"Argentina",0,"Multi-center","2024-2024",2024,2024,"RSVPreF",,,2025,"Pediatr Infect Dis J",40440704,,"10.1097/inf.0000000000004878","https://pubmed.ncbi.nlm.nih.gov/40440704","Maternal Immunization With RSVpreF Vaccine: Effectiveness in Preventing Respiratory Syncytial Virus-associated Hospitalizations in Infants Under 6 Months in Argentina: Multicenter Case-control Study"
12,"#23773","Pérez Marc 2025","Perez Marc 2025","RSV","Pregnancy","Hospitalization","Case-control","Low",1,71.3,53.3,82.3,"Argentina",0,"Multi-center","2024-2024",2024,2024,"RSVPreF",,,2025,"Lancet Infect Dis",40339585,,"10.1016/s1473-3099(25)00156-2","https://pubmed.ncbi.nlm.nih.gov/40339585","Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case-control study"
57,"#5255","Carbajal 2024","Carbajal 2024","RSV","Infant","Hospitalization","Case-control","Low",1,83,72,90,"France",0,"Single-center","2023-2024",2023,2024,"Nirsevimab",,,2024,"Lancet Child Adolesc Health",39208832,,"10.1016/s2352-4642(24)00171-8","https://pubmed.ncbi.nlm.nih.gov/39208832","Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France"
83,"#2751","Núñez 2025","Nunez 2025","RSV","Infant","Hospitalization","Case-control","Low",1,85.5,80.5,89.2,"Spain",0,"Multi-center","2023-2024",2023,2024,"Nirsevimab",,,2025,"Euro Surveill",39916606,,"10.2807/1560-7917.Es.2025.30.5.2400596","https://pubmed.ncbi.nlm.nih.gov/39916606","Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season"
81,"#2559","Moline 2025","Moline 2025","RSV","Infant","Hospitalization","Case-control","Moderate",1,93,82,97,"US",1,"Multi-center","2017-2024",2017,2024,"Nirsevimab",,,2025,"JAMA Pediatr",39652359,"PMC11667569","10.1001/jamapediatrics.2024.5572","https://pmc.ncbi.nlm.nih.gov/articles/PMC11667569","Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024"
95,"#3137","Rius-Peris 2025","Rius-Peris 2025","RSV","Infant","Hospitalization","Case-control","Moderate",1,71,50,83,"Spain",0,"Multi-center","2021-2024",2021,2024,"Nirsevimab",,,2025,"Acta Paediatr",40135713,,"10.1111/apa.70066","https://pubmed.ncbi.nlm.nih.gov/40135713","Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus-Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns"
539,"#3434","Silva-Afonso 2025","Silva-Afonso 2025","RSV","Infant","Hospitalization","Case-control","Low",1,63.8,9.6,85.5,"Spain",0,"Single-center","2022-2024",2022,2024,"Nirsevimab",,,2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA",40467410,,"10.1016/j.eimc.2025.03.006","https://pubmed.ncbi.nlm.nih.gov/40467410","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department"
74,"#7907","Lefferts 2024","Lefferts 2024","RSV","Infant","Hospitalization","Case-control","Low",1,89,32,98,"US",1,"Multi-center","2023-2024",2023,2024,"Nirsevimab",,,2024,"MMWR Morb Mortal Wkly Rep",39541241,"PMC11576050","10.15585/mmwr.mm7345a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11576050","Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024"
51,"#13170","Ares-Gómez 2024","Ares-Gomez 2024","RSV","Infant","Hospitalization","Cohort","Low",1,82,65.6,90.2,"Spain",0,"Multi-center","2023-2024",2023,2024,"Nirsevimab",,,2024,"Lancet Infect Dis",38701823,,"10.1016/s1473-3099(24)00215-9","https://pubmed.ncbi.nlm.nih.gov/38701823","Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study"
52,"#4837","Barbas Del Buey 2024","Barbas Del Buey 2024","RSV","Infant","Hospitalization","Cohort","Low",1,87.6,67.7,95.3,"Spain",0,"Multi-center","2023-2024",2023,2024,"Nirsevimab",,,2024,"Front Public Health",39220460,"PMC11361977","10.3389/fpubh.2024.1441786","https://pmc.ncbi.nlm.nih.gov/articles/PMC11361977","The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study"
60,"#5560","Coma 2024","Coma 2024","RSV","Infant","Hospitalization","Cohort","Low",1,87.6,82.1,91.4,"Spain",0,,"2023-2024",2023,2024,"Nirsevimab",,,2024,"Arch Dis Child",38857952,"PMC11347209","10.1136/archdischild-2024-327153","https://pmc.ncbi.nlm.nih.gov/articles/PMC11347209","Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)"
104,"#3727","Torres 2025","Torres 2025","RSV","Infant","Hospitalization","Cohort","Low",1,76.41,72.57,79.72,"Chile",0,"Multi-center","2019-2024",2019,2024,"Nirsevimab",,,2025,"Lancet Infect Dis",40513593,,"10.1016/s1473-3099(25)00233-6","https://pubmed.ncbi.nlm.nih.gov/40513593","Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study"
89,"#2956","Perramon-Malavez 2025","Perramon-Malavez 2025","RSV","Infant","Hospitalization","Cohort","Low",1,74,61,83,"Spain, Italy, England",0,"Multi-center","2018-2024",2018,2024,"Nirsevimab",,,2025,"The Lancet Regional Health - Europe",40950943,"PMC12426819","10.1016/j.lanepe.2025.101334","https://pmc.ncbi.nlm.nih.gov/articles/PMC12426819","Real-world impact of nirsevimab immunisation against respiratory disease on emergency department attendances and admissions among infants: a multinational retrospective analysis"
645,"#40039","Jabagi 2025","Jabagi 2025","RSV","Infant","Hospitalization","Cohort","Low",1,65,61,69,"France",0,"Nationwide","2023-2024",2023,2024,"Nirsevimab",,,2025,"NEJM evidence",39998305,,"10.1056/EVIDoa2400275","https://pubmed.ncbi.nlm.nih.gov/39998305","Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants."
52,"#4837","Barbas Del Buey 2024","Barbas Del Buey 2024","RSV","Infant","ICU admission","Cohort","Low",1,90.7,-3.6,99.2,"Spain",0,"Multi-center","2023-2024",2023,2024,"Nirsevimab",,,2024,"Front Public Health",39220460,"PMC11361977","10.3389/fpubh.2024.1441786","https://pmc.ncbi.nlm.nih.gov/articles/PMC11361977","The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study"
60,"#5560","Coma 2024","Coma 2024","RSV","Infant","ICU admission","Cohort","Low",1,90.1,76.3,95.9,"Spain",0,,"2023-2024",2023,2024,"Nirsevimab",,,2024,"Arch Dis Child",38857952,"PMC11347209","10.1136/archdischild-2024-327153","https://pmc.ncbi.nlm.nih.gov/articles/PMC11347209","Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)"
88,"#2957","Perramon-Malavez 2025","Perramon-Malavez 2025","RSV","Infant","ICU admission","Cohort","Low",1,85,72,93,"Spain",0,"Population-based","2023-2024",2023,2024,"Nirsevimab",,,2025,"Pediatr Infect Dis J",39823640,,"10.1097/inf.0000000000004672","https://pubmed.ncbi.nlm.nih.gov/39823640","Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-related Outcomes in Hospital Care Settings: A Seasonal Cohort Study of Infants in Catalonia, Spain"
104,"#3727","Torres 2025","Torres 2025","RSV","Infant","ICU admission","Cohort","Low",1,84.94,79.47,88.95,"Chile",0,"Multi-center","2019-2024",2019,2024,"Nirsevimab",,,2025,"Lancet Infect Dis",40513593,,"10.1016/s1473-3099(25)00233-6","https://pubmed.ncbi.nlm.nih.gov/40513593","Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study"
645,"#40039","Jabagi 2025","Jabagi 2025","RSV","Infant","ICU admission","Cohort","Low",1,74,56,85,"France",0,"Nationwide","2023-2024",2023,2024,"Nirsevimab",,,2025,"NEJM evidence",39998305,,"10.1056/EVIDoa2400275","https://pubmed.ncbi.nlm.nih.gov/39998305","Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants."
57,"#5255","Carbajal 2024","Carbajal 2024","RSV","Infant","Medically-attended infection","Case-control","Low",1,83,71,90,"France",0,"Single-center","2023-2024",2023,2024,"Nirsevimab",,,2024,"Lancet Child Adolesc Health",39208832,,"10.1016/s2352-4642(24)00171-8","https://pubmed.ncbi.nlm.nih.gov/39208832","Real-world effectiveness of nirsevimab immunisation against bronchiolitis in infants: a case-control study in Paris, France"
81,"#2559","Moline 2025","Moline 2025","RSV","Infant","Medically-attended infection","Case-control","Moderate",1,89,79,94,"US",1,"Multi-center","2017-2024",2017,2024,"Nirsevimab",,,2025,"JAMA Pediatr",39652359,"PMC11667569","10.1001/jamapediatrics.2024.5572","https://pmc.ncbi.nlm.nih.gov/articles/PMC11667569","Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024"
74,"#7907","Lefferts 2024","Lefferts 2024","RSV","Infant","Medically-attended infection","Case-control","Low",1,76,42,90,"US",1,"Multi-center","2023-2024",2023,2024,"Nirsevimab",,,2024,"MMWR Morb Mortal Wkly Rep",39541241,"PMC11576050","10.15585/mmwr.mm7345a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11576050","Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children - Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024"
551,"#10420","Surie 2024","Surie 2024","RSV","Elder","Hospitalization","Case-control","Low",1,75,50,87,"US",1,"Multi-center","2023-2024",2023,2024,"Abrysvo and Arexvy","≥60y",,2024,"Jama",39230920,"PMC11375516","10.1001/jama.2024.15775","https://pmc.ncbi.nlm.nih.gov/articles/PMC11375516","RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older"
561,"#10507","Tartof 2024","Tartof 2024","RSV","Elder","Hospitalization","Case-control","Low",1,90,20,99,"US",1,"Kaiser Permanente Southern California","2023-2024",2023,2024,"Abrysvo","≥60y",,2024,"JAMA Netw Open",39671195,"PMC11645642","10.1001/jamanetworkopen.2024.50832","https://pmc.ncbi.nlm.nih.gov/articles/PMC11645642","Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Lower Respiratory Tract Disease"
494,"#9227","Payne 2024","Payne 2024","RSV","Elder","Hospitalization","Case-control","Low",1,80,71,85,"US",1,"Multi-center","2023-2024",2023,2024,"Abrysvo and Arexvy","≥60y",,2024,"Lancet",39426837,,"10.1016/s0140-6736(24)01738-0","https://pubmed.ncbi.nlm.nih.gov/39426837","Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis"
102,"#19044","Tenforde 2024","Tenforde 2024","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,58,44,69,"US",1,"Multi-center","2023-2024",2023,2024,"IIV",,,2024,"Clin Infect Dis",39656838,"PMC12287760","10.1093/cid/ciae597","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287760","Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States"
99,"#24371","Shinjoh 2025","Shinjoh 2025","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,73,57,83,"Japan",0,"Multi-center","2024-2025",2024,2025,"IIV",,,2025,"Vaccine",40578174,,"10.1016/j.vaccine.2025.127429","https://pubmed.ncbi.nlm.nih.gov/40578174","Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated vaccine and limited use of newly introduced live-attenuated vaccine"
11,"#9276","Pérez-Gimeno 2024","Perez-Gimeno 2024","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,77,21,93,"Spain",0,"SiVIRA database","2023-2024",2023,2024,"IIV",,,2024,"Euro Surveill",39364601,,"10.2807/1560-7917.Es.2024.29.40.2400618","https://pubmed.ncbi.nlm.nih.gov/39364601","Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24"
295,"#6300","Frutos 2024, NVSN","Frutos 2024","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,61,40,75,"US",1,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
295,"#6300","Frutos 2024, VISION","Frutos 2024","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,52,16,72,"US",1,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
296,"#1265","Frutos 2025, NVSN","Frutos 2025","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,63,41,76,"US",1,"Multi-center","2024-2025",2024,2025,"Seasonal",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
296,"#1265","Frutos 2025, VISION","Frutos 2025","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,78,60,89,"US",1,"Multi-center","2024-2025",2024,2025,"Seasonal",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
406,"#22737","Gharpure 2025, Australia","Lewis 2025","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,88,77,93,"US",1,"Multi-center","2023-2024",2023,2024,"Not stated",,,2025,"J Infect Dis",40198276,,"10.1093/infdis/jiaf185","https://pubmed.ncbi.nlm.nih.gov/40198276","Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024"
406,"#22737","Gharpure 2025, Brazil","Lewis 2025","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,46,14,66,"US",1,"Multi-center","2023-2024",2023,2024,"Not stated",,,2025,"J Infect Dis",40198276,,"10.1093/infdis/jiaf185","https://pubmed.ncbi.nlm.nih.gov/40198276","Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024"
406,"#22737","Gharpure 2025, Chile","Lewis 2025","Influenza","Infant/Child","Hospitalization","Case-control","Low",1,71,41,86,"US",1,"Multi-center","2023-2024",2023,2024,"Not stated",,,2025,"J Infect Dis",40198276,,"10.1093/infdis/jiaf185","https://pubmed.ncbi.nlm.nih.gov/40198276","Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024"
102,"#19044","Tenforde 2024","Tenforde 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,58,56,60,"US",1,"Multi-center","2023-2024",2023,2024,"IIV",,,2024,"Clin Infect Dis",39656838,"PMC12287760","10.1093/cid/ciae597","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287760","Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States"
11,"#9276","Pérez-Gimeno 2024","Perez-Gimeno 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,70,51,81,"Spain",0,"SiVIRA database","2023-2024",2023,2024,"IIV",,,2024,"Euro Surveill",39364601,,"10.2807/1560-7917.Es.2024.29.40.2400618","https://pubmed.ncbi.nlm.nih.gov/39364601","Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24"
99,"#24371","Shinjoh 2025","Shinjoh 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,57,24,75,"Japan",0,"Multi-center","2024-2025",2024,2025,"IIV",,,2025,"Vaccine",40578174,,"10.1016/j.vaccine.2025.127429","https://pubmed.ncbi.nlm.nih.gov/40578174","Influenza vaccination in Japanese children, 2024/25: Effectiveness of inactivated vaccine and limited use of newly introduced live-attenuated vaccine"
255,"#5595","Costantino 2024","Costantino 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,38,-1,62,"Italy",0,"RespiVirNet network","2023-2024",2023,2024,"IIV",,,2024,"Vaccines",38543939,"PMC10976042","10.3390/vaccines12030305","https://pmc.ncbi.nlm.nih.gov/articles/PMC10976042","Mid-Term Estimates of Influenza Vaccine Effectiveness against the A(H1N1)pdm09 Prevalent Circulating Subtype in the 2023/24 Season: Data from the Sicilian RespiVirNet Surveillance System"
295,"#6300","Frutos 2024, NVSN","Frutos 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,59,48,67,"US",1,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
295,"#6300","Frutos 2024, US Flu VE","Frutos 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,67,48,80,"US",1,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
295,"#6300","Frutos 2024, VISION","Frutos 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,60,57,64,"US",1,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
278,"#1117","Erdwiens 2025","Erdwiens 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,58,13,80,"Germany",0,"Nationwide","2024-2025",2024,2025,"Not stated",,,2025,"Influenza Other Respir Viruses",40328669,"PMC12055342","10.1111/irv.70115","https://pmc.ncbi.nlm.nih.gov/articles/PMC12055342","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance"
377,"#1921","Kissling 2025","Kissling 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","High",1,70,61,78,"Europe",0,"VEBIS network","2023-2024",2023,2024,"Seasonal",,,2025,"Euro Surveill",40511473,,"10.2807/1560-7917.Es.2025.30.23.2500011","https://pubmed.ncbi.nlm.nih.gov/40511473","Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24"
350,"#1735","Jiang 2025","Jiang 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","High",1,57,49,64,"China",0,,"2023-2024",2023,2024,"Seasonal",,,2025,"Emerg Microbes Infect",40192342,"PMC12164376","10.1080/22221751.2025.2490531","https://pmc.ncbi.nlm.nih.gov/articles/PMC12164376","Influenza vaccine effectiveness among primary and secondary school students in Shenzhen during the 2023/24 influenza season"
296,"#1265","Frutos 2025, NVSN","Frutos 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,59,47,68,"US",1,"Multi-center","2024-2025",2024,2025,"Seasonal",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
296,"#1265","Frutos 2025, US Flu VE","Frutos 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,32,1,54,"US",1,"Multi-center","2024-2025",2024,2025,"Seasonal",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
296,"#1265","Frutos 2025, VISION","Frutos 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,60,56,63,"US",1,"Multi-center","2024-2025",2024,2025,"Seasonal",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
253,"#21056","Chung 2025","Chung 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,68,51,79,"US",1,"Flu VE Network","2023-2024",2023,2024,"Seasonal",,,2025,"Clin Infect Dis",39761230,"PMC12287938","10.1093/cid/ciae658","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287938","Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season"
166,"#24","Abou Chakra 2025","Abou Chakra 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,82,46,93,"France",0,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2025,"Emerg Microbes Infect",40071892,"PMC11980197","10.1080/22221751.2025.2466699","https://pmc.ncbi.nlm.nih.gov/articles/PMC11980197","Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024"
299,"#6372","Gào 2024","Gao 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,46,43,49,"China",0,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"Open Forum Infectious Diseases",39220659,"PMC11365065","10.1093/ofid/ofae456","https://pmc.ncbi.nlm.nih.gov/articles/PMC11365065","Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season"
445,"#8593","Mi 2024","Mi 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Moderate",1,63,33,80,"China",0,"Multi-center","2024-2024",2024,2024,"Seasonal",,,2024,"Hum Vaccin Immunother",39208849,"PMC11364069","10.1080/21645515.2024.2394255","https://pmc.ncbi.nlm.nih.gov/articles/PMC11364069","Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study"
617,"#11574","Zhu 2024","Zhu 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Moderate",1,56,54,57,"US",1,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"MMWR Morb Mortal Wkly Rep",38421946,"PMC10907038","10.15585/mmwr.mm7308a4","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907038","Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024"
619,"#4272","Zhu 2025, A","Zhu 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,32,19,43,"China",0,"Single-center","2021-2024",2021,2024,"Seasonal",,,2025,"Vaccines",39852783,"PMC11768588","10.3390/vaccines13010004","https://pmc.ncbi.nlm.nih.gov/articles/PMC11768588","Evaluation of Influenza Vaccine Effectiveness from 2021 to 2024: A Guangdong-Based Test-Negative CaseControl Study"
618,"#25499","Zhu 2025, B","Zhu 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,53,51,54,"US",1,"Population-based","2023-2024",2023,2024,"Seasonal",,,2025,"J Infect Dis",40359401,"PMC12353657","10.1093/infdis/jiaf248","https://pmc.ncbi.nlm.nih.gov/articles/PMC12353657","Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season"
615,"#4195","Zhang 2025","Zhang 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Moderate",1,51,5,75,"China",0,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2025,"Vaccine",39731809,,"10.1016/j.vaccine.2024.126662","https://pubmed.ncbi.nlm.nih.gov/39731809","Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season"
613,"#11414","Zeno 2024","Zeno 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,39,26,50,"South America",0,"REVELAC-i network","2024-2024",2024,2024,"Seasonal",,,2024,"MMWR Morb Mortal Wkly Rep",39361525,"PMC11449270","10.15585/mmwr.mm7339a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11449270","Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024"
541,"#10228","Skowronski 2024","Skowronski 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,60,34,76,"Canada",0,"Sentinel Practitioner Surveillance Network","2023-2024",2023,2024,"Mixed",,,2024,"Euro Surveill",38362622,,"10.2807/1560-7917.Es.2024.29.7.2400076","https://pubmed.ncbi.nlm.nih.gov/38362622","2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)"
544,"#10254","Smolarchuk 2024","Smolarchuk 2024","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,74,66,99,"Canada",0,,"2023-2023",2023,2023,"Mixed",,,2024,"Euro Surveill",38214082,,"10.2807/1560-7917.Es.2024.29.2.2300709","https://pubmed.ncbi.nlm.nih.gov/38214082","Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season"
632,"#39262","Nguyen 2025","Nguyen 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Low",1,69,52,81,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"J Pediatric Infect Dis Soc",40736196,"PMC12392406","10.1093/jpids/piaf069","https://pmc.ncbi.nlm.nih.gov/articles/PMC12392406","Effectiveness of cell culture-based influenza vaccine, 2023-2024"
549,"#3602","Sun 2025","Sun 2025","Influenza","Infant/Child","Medically-attended infection","Case-control","Moderate",1,58,15,81,"China",0,,"2024-2025",2024,2025,"IIV",,,2025,"Euro Surveill",39980425,,"10.2807/1560-7917.Es.2025.30.7.2500084","https://pubmed.ncbi.nlm.nih.gov/39980425","Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season"
253,"#21056","Chung 2025","Chung 2025","Influenza","Child","Medically-attended infection","Case-control","Low",1,59,35,75,"US",1,"Flu VE Network","2023-2024",2023,2024,"Seasonal",,,2025,"Clin Infect Dis",39761230,"PMC12287938","10.1093/cid/ciae658","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287938","Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season"
166,"#24","Abou Chakra 2025","Abou Chakra 2025","Influenza","Child","Medically-attended infection","Case-control","Low",1,56,32,72,"France",0,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2025,"Emerg Microbes Infect",40071892,"PMC11980197","10.1080/22221751.2025.2466699","https://pmc.ncbi.nlm.nih.gov/articles/PMC11980197","Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024"
299,"#6372","Gào 2024","Gao 2024","Influenza","Child","Medically-attended infection","Case-control","Low",1,38.6,35.7,41.5,"China",0,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"Open Forum Infectious Diseases",39220659,"PMC11365065","10.1093/ofid/ofae456","https://pmc.ncbi.nlm.nih.gov/articles/PMC11365065","Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season"
445,"#8593","Mi 2024","Mi 2024","Influenza","Child","Medically-attended infection","Case-control","Moderate",1,-23,-56,35,"China",0,"Multi-center","2024-2024",2024,2024,"Seasonal",,,2024,"Hum Vaccin Immunother",39208849,"PMC11364069","10.1080/21645515.2024.2394255","https://pmc.ncbi.nlm.nih.gov/articles/PMC11364069","Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study"
434,"#8432","Marron 2024","Marron 2024","Influenza","Child","Medically-attended infection","Case-control","Low",1,68,30,87,"Ireland",0,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2024,"Influenza Other Respir Viruses",39623514,"PMC11611713","10.1111/irv.70023","https://pmc.ncbi.nlm.nih.gov/articles/PMC11611713","Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland"
615,"#4195","Zhang 2025","Zhang 2025","Influenza","Child","Medically-attended infection","Case-control","Moderate",1,34,21,44,"China",0,"Multi-center","2023-2024",2023,2024,"Seasonal",,,2025,"Vaccine",39731809,,"10.1016/j.vaccine.2024.126662","https://pubmed.ncbi.nlm.nih.gov/39731809","Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season"
544,"#10254","Smolarchuk 2024","Smolarchuk 2024","Influenza","Child","Medically-attended infection","Case-control","Low",1,62,32,78,"Canada",0,,"2023-2023",2023,2023,"Mixed",,,2024,"Euro Surveill",38214082,,"10.2807/1560-7917.Es.2024.29.2.2300709","https://pubmed.ncbi.nlm.nih.gov/38214082","Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season"
585,"#19530","Whitaker 2024, GB-PC","Whitaker 2024","Influenza","Child","Medically-attended infection","Case-control","Moderate",1,65,41,79,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
585,"#19530","Whitaker 2024, EN-H","Whitaker 2024","Influenza","Child","Medically-attended infection","Case-control","Moderate",1,63,46,75,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
585,"#19530","Whitaker 2024, SC-H","Whitaker 2024","Influenza","Child","Medically-attended infection","Case-control","Moderate",1,65,52,74,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
549,"#3602","Sun 2025","Sun 2025","Influenza","Child","Medically-attended infection","Case-control","Moderate",1,35,12,52,"China",0,,"2024-2025",2024,2025,"IIV",,,2025,"Euro Surveill",39980425,,"10.2807/1560-7917.Es.2025.30.7.2500084","https://pubmed.ncbi.nlm.nih.gov/39980425","Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season"
512,"#3168","Rose 2025, Denmark","Rose 2025","Influenza","Adult","Hospitalization","Case-control","High",1,44,28,57,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, England","Rose 2025","Influenza","Adult","Hospitalization","Case-control","High",1,53,46,59,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, EU","Rose 2025","Influenza","Adult","Hospitalization","Case-control","High",1,52,16,74,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, Northern Ireland","Rose 2025","Influenza","Adult","Hospitalization","Case-control","High",1,72,39,87,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, Scotland","Rose 2025","Influenza","Adult","Hospitalization","Case-control","High",1,28,13,40,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
296,"#1265","Frutos 2025, IVY","Frutos 2025","Influenza","Adult","Hospitalization","Case-control","Low",1,48,28,63,"US",1,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
296,"#1265","Frutos 2025, VISION","Frutos 2025","Influenza","Adult","Hospitalization","Case-control","Low",1,51,41,59,"US",1,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
439,"#8492","Maurel 2024","Maurel 2024","Influenza","Adult","Hospitalization","Case-control","High",1,53,31,68,"Europe",0,"VEBIS network","2023-2024",2023,2024,"Mixed",,,2024,"Euro Surveill",38390651,,"10.2807/1560-7917.Es.2024.29.8.2400089","https://pubmed.ncbi.nlm.nih.gov/38390651","Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024"
295,"#6300","Frutos 2024, IVY","Frutos 2024","Influenza","Adult/Elder","Hospitalization","Case-control","Low",1,44,32,54,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
295,"#6300","Frutos 2024, VISION","Frutos 2024","Influenza","Adult/Elder","Hospitalization","Case-control","Low",1,41,34,47,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
278,"#1117","Erdwiens 2025","Erdwiens 2025","Influenza","Adult/Elder","Hospitalization","Case-control","Low",1,76,27,92,"Germany",0,"Nationwide","2024-2025",2024,2025,"Mixed",,,2025,"Influenza Other Respir Viruses",40328669,"PMC12055342","10.1111/irv.70115","https://pmc.ncbi.nlm.nih.gov/articles/PMC12055342","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance"
295,"#6300","Frutos 2024, IVY","Frutos 2024","Influenza","Elder","Hospitalization","Case-control","Low",1,42,23,56,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
295,"#6300","Frutos 2024, VISION","Frutos 2024","Influenza","Elder","Hospitalization","Case-control","Low",1,42,34,50,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
296,"#1265","Frutos 2025, IVY","Frutos 2025","Influenza","Elder","Hospitalization","Case-control","Low",1,38,19,52,"US",1,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
296,"#1265","Frutos 2025, VISION","Frutos 2025","Influenza","Elder","Hospitalization","Case-control","Low",1,57,52,61,"US",1,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
406,"#22737","Lewis 2025","Lewis 2025","Influenza","Elder","Hospitalization","Case-control","Low",1,31,16,43,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"J Infect Dis",40198276,,"10.1093/infdis/jiaf185","https://pubmed.ncbi.nlm.nih.gov/40198276","Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations-United States, September 1, 2023-May 31, 2024"
435,"#2405","Martínez-Baz 2025","Martinez-Baz 2025","Influenza","Elder","Hospitalization","Case-control","Low",1,28,6,45,"Spain",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"Int J Infect Dis",39694231,"PMC11735411","10.1016/j.ijid.2024.107364","https://pmc.ncbi.nlm.nih.gov/articles/PMC11735411","Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study"
512,"#3168","Rose 2025, Denmark","Rose 2025","Influenza","Elder","Hospitalization","Case-control","High",1,55,47,62,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, England","Rose 2025","Influenza","Elder","Hospitalization","Case-control","High",1,48,42,53,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, EU","Rose 2025","Influenza","Elder","Hospitalization","Case-control","High",1,49,34,61,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, Northern Ireland","Rose 2025","Influenza","Elder","Hospitalization","Case-control","High",1,52,20,72,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, Scotland","Rose 2025","Influenza","Elder","Hospitalization","Case-control","High",1,29,23,36,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
439,"#8492","Maurel 2024","Maurel 2024","Influenza","Elder","Hospitalization","Case-control","High",1,36,22,47,"Europe",0,"VEBIS network","2023-2024",2023,2024,"Mixed",,,2024,"Euro Surveill",38390651,,"10.2807/1560-7917.Es.2024.29.8.2400089","https://pubmed.ncbi.nlm.nih.gov/38390651","Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024"
307,"#1336","Gharpure 2025, Australia","Gharpure 2025","Influenza","Elder","Hospitalization","Case-control","High",1,59,45,70,"Argentina, Brazil, Chile, Paraguay, Uruguay, Australia, New Zealand, Thailand",0,"Multi-center","2022-2023",2022,2023,"Mixed",,,2025,"Lancet Glob Health",39890222,,"10.1016/s2214-109x(24)00473-x","https://pubmed.ncbi.nlm.nih.gov/39890222","Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design"
307,"#1336","Gharpure 2025, Brazil","Gharpure 2025","Influenza","Elder","Hospitalization","Case-control","High",1,14,-19,39,"Argentina, Brazil, Chile, Paraguay, Uruguay, Australia, New Zealand, Thailand",0,"Multi-center","2022-2023",2022,2023,"Mixed",,,2025,"Lancet Glob Health",39890222,,"10.1016/s2214-109x(24)00473-x","https://pubmed.ncbi.nlm.nih.gov/39890222","Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design"
307,"#1336","Gharpure 2025, Chile","Gharpure 2025","Influenza","Elder","Hospitalization","Case-control","High",1,40,12,59,"Argentina, Brazil, Chile, Paraguay, Uruguay, Australia, New Zealand, Thailand",0,"Multi-center","2022-2023",2022,2023,"Mixed",,,2025,"Lancet Glob Health",39890222,,"10.1016/s2214-109x(24)00473-x","https://pubmed.ncbi.nlm.nih.gov/39890222","Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design"
307,"#1336","Gharpure 2025, New Zealand","Gharpure 2025","Influenza","Elder","Hospitalization","Case-control","High",1,72,35,88,"Argentina, Brazil, Chile, Paraguay, Uruguay, Australia, New Zealand, Thailand",0,"Multi-center","2022-2023",2022,2023,"Mixed",,,2025,"Lancet Glob Health",39890222,,"10.1016/s2214-109x(24)00473-x","https://pubmed.ncbi.nlm.nih.gov/39890222","Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design"
102,"#19044","Tenforde 2024","Tenforde 2024","Influenza","Elder","Hospitalization","Case-control","Low",1,36,31,41,"US",1,"Multi-center","2023-2024",2023,2024,"IIV",,,2024,"Clin Infect Dis",39656838,"PMC12287760","10.1093/cid/ciae597","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287760","Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States"
276,"#1107","Emborg 2025","Emborg 2025","Influenza","Elder","Hospitalization","Case-control","Low",1,36,23,47,"Denmark",0,"Nationwide","2024-2025",2024,2025,"IIV",,,2025,"Euro Surveill",40156348,,"10.2807/1560-7917.Es.2025.30.12.2500174","https://pubmed.ncbi.nlm.nih.gov/40156348","Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025"
539,"#3434","Silva-Afonso 2025","Silva-Afonso 2025","Influenza","Elder","Hospitalization","Case-control","Low",1,39,15,56,"Spain",0,"Single-center","2022-2024",2022,2024,"Mixed",,,2025,"ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA",40467410,,"10.1016/j.eimc.2025.03.006","https://pubmed.ncbi.nlm.nih.gov/40467410","Effectiveness of immunization strategies for preventing severe acute respiratory infection during the 2023/2024 season in a Spanish health department"
248,"#5489","Choi 2024","Choi 2024","Influenza","Adult","Medically-attended infection","Case-control","High",1,24.3,5.3,39.5,"South Korea",0,"Multi-center","2023-2023",2023,2023,"Other/combined",,,2024,"J Korean Med Sci",38651226,"PMC11035711","10.3346/jkms.2024.39.e146","https://pmc.ncbi.nlm.nih.gov/articles/PMC11035711","Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea"
278,"#1117","Erdwiens 2025","Erdwiens 2025","Influenza","Adult","Medically-attended infection","Case-control","Low",1,6,-65,46,"Germany",0,"Nationwide","2024-2025",2024,2025,"Other/combined",,,2025,"Influenza Other Respir Viruses",40328669,"PMC12055342","10.1111/irv.70115","https://pmc.ncbi.nlm.nih.gov/articles/PMC12055342","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness in Germany-Data From Primary Care and Hospital Sentinel Surveillance"
296,"#1265","Frutos 2025, Flu VE","Frutos 2025","Influenza","Adult","Medically-attended infection","Case-control","Low",1,37,16,53,"US",1,"Multi-center","2024-2025",2024,2025,"Other/combined",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
296,"#1265","Frutos 2025, VISION","Frutos 2025","Influenza","Adult","Medically-attended infection","Case-control","Low",1,56,53,58,"US",1,"Multi-center","2024-2025",2024,2025,"Other/combined",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
299,"#6372","Gào 2024","Gao 2024","Influenza","Adult","Medically-attended infection","Case-control","Low",1,46.7,37,55,"China",0,"Multi-center","2023-2024",2023,2024,"Other/combined",,,2024,"Open Forum Infectious Diseases",39220659,"PMC11365065","10.1093/ofid/ofae456","https://pmc.ncbi.nlm.nih.gov/articles/PMC11365065","Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season"
377,"#1921","Kissling 2025","Kissling 2025","Influenza","Adult","Medically-attended infection","Case-control","High",1,41,30,49,"Europe",0,"VEBIS network","2023-2024",2023,2024,"Other/combined",,,2025,"Euro Surveill",40511473,,"10.2807/1560-7917.Es.2025.30.23.2500011","https://pubmed.ncbi.nlm.nih.gov/40511473","Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24"
382,"#22585","Kwaah 2025","Kwaah 2025","Influenza","Adult","Medically-attended infection","Case-control","High",1,17,-35,49,"US",1,"Nationwide (military healthcare)","2024-2025",2024,2025,"Other/combined",,,2025,"MSMR",40455969,"PMC12186818",,"https://pmc.ncbi.nlm.nih.gov/articles/PMC12186818","Mid-season vaccine effectiveness estimates for influenza: the Department of Defense Global Respiratory Pathogen Surveillance Program, 2024-2025 season"
434,"#8432","Marron 2024","Marron 2024","Influenza","Adult","Medically-attended infection","Case-control","Low",1,35,9,54,"Ireland",0,"Multi-center","2023-2024",2023,2024,"Other/combined",,,2024,"Influenza Other Respir Viruses",39623514,"PMC11611713","10.1111/irv.70023","https://pmc.ncbi.nlm.nih.gov/articles/PMC11611713","Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland"
439,"#8492","Maurel 2024","Maurel 2024","Influenza","Adult","Medically-attended infection","Case-control","High",1,40,22,55,"Europe",0,"VEBIS network","2023-2024",2023,2024,"Other/combined",,,2024,"Euro Surveill",38390651,,"10.2807/1560-7917.Es.2024.29.8.2400089","https://pubmed.ncbi.nlm.nih.gov/38390651","Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024"
512,"#3168","Rose 2025, Denmark","Rose 2025","Influenza","Adult","Medically-attended infection","Case-control","High",1,52,44,58,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Other/combined",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, EU","Rose 2025","Influenza","Adult","Medically-attended infection","Case-control","High",1,42,21,58,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Other/combined",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, England","Rose 2025","Influenza","Adult","Medically-attended infection","Case-control","High",1,47,36,56,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Other/combined",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
541,"#10228","Skowronski 2024","Skowronski 2024","Influenza","Adult","Medically-attended infection","Case-control","Low",1,54,38,66,"Canada",0,"Sentinel Practitioner Surveillance Network","2023-2024",2023,2024,"Mixed",,,2024,"Euro Surveill",38362622,,"10.2807/1560-7917.Es.2024.29.7.2400076","https://pubmed.ncbi.nlm.nih.gov/38362622","2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)"
544,"#10254","Smolarchuk 2024","Smolarchuk 2024","Influenza","Adult","Medically-attended infection","Case-control","Low",1,62,57,67,"Canada",0,,"2023-2023",2023,2023,"Mixed",,,2024,"Euro Surveill",38214082,,"10.2807/1560-7917.Es.2024.29.2.2300709","https://pubmed.ncbi.nlm.nih.gov/38214082","Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season"
585,"#19530","Whitaker 2024, GB-PC","Whitaker 2024","Influenza","Adult","Medically-attended infection","Case-control","Moderate",1,55,43,65,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
585,"#19530","Whitaker 2024, EN-H","Whitaker 2024","Influenza","Adult","Medically-attended infection","Case-control","Moderate",1,36,20,49,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
585,"#19530","Whitaker 2024, SC-H","Whitaker 2024","Influenza","Adult","Medically-attended infection","Case-control","Moderate",1,51,40,59,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
615,"#4195","Zhang 2025","Zhang 2025","Influenza","Adult","Medically-attended infection","Case-control","Moderate",1,72.4,57.34,82.11,"China",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"Vaccine",39731809,,"10.1016/j.vaccine.2024.126662","https://pubmed.ncbi.nlm.nih.gov/39731809","Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season"
399,"#2089","Lei 2025","Lei 2025","Influenza","Adult","Medically-attended infection","Case-control","Low",1,52,43,58,"China",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"Hum Vaccin Immunother",39704470,,"10.1080/21645515.2024.2435156","https://pubmed.ncbi.nlm.nih.gov/39704470","Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China"
631,"#39260","Reeves 2025","Reeves 2025","Influenza","Adult","Medically-attended infection","Case-control","Low",1,54,51,56,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"Vaccine",40660660,"PMC12305427","10.1016/j.vaccine.2025.127483","https://pmc.ncbi.nlm.nih.gov/articles/PMC12305427","Effectiveness of 2023-2024 seasonal influenza vaccine against influenza-associated emergency department and urgent care encounters among pregnant and non-pregnant women of reproductive age"
632,"#39262","Nguyen 2025","Nguyen 2025","Influenza","Adult","Medically-attended infection","Case-control","Low",1,50,29,65,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"J Pediatric Infect Dis Soc",40736196,"PMC12392406","10.1093/jpids/piaf069","https://pmc.ncbi.nlm.nih.gov/articles/PMC12392406","Effectiveness of cell culture-based influenza vaccine, 2023-2024"
445,"#8593","Mi 2024","Mi 2024","Influenza","Adult","Medically-attended infection","Case-control","Moderate",1,60,26,79,"China",0,"Multi-center","2024-2024",2024,2024,"Not stated",,,2024,"Hum Vaccin Immunother",39208849,"PMC11364069","10.1080/21645515.2024.2394255","https://pmc.ncbi.nlm.nih.gov/articles/PMC11364069","Real-world effectiveness of influenza vaccine against medical-attended influenza infection during 2023/24 season in Ili Kazakh Autonomous Prefecture, China: A test-negative, case-control study"
166,"#24","Abou Chakra 2025","Abou Chakra 2025","Influenza","Adult","Medically-attended infection","Case-control","Low",1,52.87,48.63,56.82,"France",0,"Multi-center","2023-2024",2023,2024,"IIV",,,2025,"Emerg Microbes Infect",40071892,"PMC11980197","10.1080/22221751.2025.2466699","https://pmc.ncbi.nlm.nih.gov/articles/PMC11980197","Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024"
549,"#3602","Sun 2025","Sun 2025","Influenza","Adult","Medically-attended infection","Case-control","Moderate",1,83.9,64.1,94,"China",0,,"2024-2025",2024,2025,"IIV",,,2025,"Euro Surveill",39980425,,"10.2807/1560-7917.Es.2025.30.7.2500084","https://pubmed.ncbi.nlm.nih.gov/39980425","Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season"
248,"#5489","Choi 2024","Choi 2024","Influenza","Elder","Medically-attended infection","Case-control","High",1,17.4,-17.1,41.8,"South Korea",0,"Multi-center","2023-2023",2023,2023,"Mixed",,,2024,"J Korean Med Sci",38651226,"PMC11035711","10.3346/jkms.2024.39.e146","https://pmc.ncbi.nlm.nih.gov/articles/PMC11035711","Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea"
295,"#6300","Frutos 2024, Flu VE","Frutos 2024","Influenza","Elder","Medically-attended infection","Case-control","Low",1,51,14,72,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
295,"#6300","Frutos 2024, VISION","Frutos 2024","Influenza","Elder","Medically-attended infection","Case-control","Low",1,41,36,45,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
296,"#1265","Frutos 2025, Flu VE","Frutos 2025","Influenza","Elder","Medically-attended infection","Case-control","Low",1,18,-69,60,"US",1,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
296,"#1265","Frutos 2025, VISION","Frutos 2025","Influenza","Elder","Medically-attended infection","Case-control","Low",1,51,47,54,"US",1,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"MMWR Morb Mortal Wkly Rep",40014791,"PMC11867582","10.15585/mmwr.mm7406a2","https://pmc.ncbi.nlm.nih.gov/articles/PMC11867582","Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025"
299,"#6372","Gào 2024","Gao 2024","Influenza","Elder","Medically-attended infection","Case-control","Low",1,46.1,33.7,48.7,"China",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Open Forum Infectious Diseases",39220659,"PMC11365065","10.1093/ofid/ofae456","https://pmc.ncbi.nlm.nih.gov/articles/PMC11365065","Population-Based Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Infection in Southern China, 2023-2024 Season"
377,"#1921","Kissling 2025","Kissling 2025","Influenza","Elder","Medically-attended infection","Case-control","High",1,49,35,60,"Europe",0,"VEBIS network","2023-2024",2023,2024,"Mixed",,,2025,"Euro Surveill",40511473,,"10.2807/1560-7917.Es.2025.30.23.2500011","https://pubmed.ncbi.nlm.nih.gov/40511473","Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24"
399,"#2089","Lei 2025","Lei 2025","Influenza","Elder","Medically-attended infection","Case-control","Low",1,25,4,41,"China",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"Hum Vaccin Immunother",39704470,,"10.1080/21645515.2024.2435156","https://pubmed.ncbi.nlm.nih.gov/39704470","Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China"
434,"#8432","Marron 2024","Marron 2024","Influenza","Elder","Medically-attended infection","Case-control","Low",1,16,-83,60,"Ireland",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",39623514,"PMC11611713","10.1111/irv.70023","https://pmc.ncbi.nlm.nih.gov/articles/PMC11611713","Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland"
439,"#8492","Maurel 2024","Maurel 2024","Influenza","Elder","Medically-attended infection","Case-control","High",1,45,22,62,"Europe",0,"VEBIS network","2023-2024",2023,2024,"Mixed",,,2024,"Euro Surveill",38390651,,"10.2807/1560-7917.Es.2024.29.8.2400089","https://pubmed.ncbi.nlm.nih.gov/38390651","Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024"
512,"#3168","Rose 2025, Denmark","Rose 2025","Influenza","Elder","Medically-attended infection","Case-control","High",1,55,44,64,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, EU","Rose 2025","Influenza","Elder","Medically-attended infection","Case-control","High",1,0,-54,34,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
512,"#3168","Rose 2025, England","Rose 2025","Influenza","Elder","Medically-attended infection","Case-control","High",1,38,18,53,"England, Northern Ireland, Scotland, Denmark",0,"Multi-center","2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980423,,"10.2807/1560-7917.Es.2025.30.7.2500102","https://pubmed.ncbi.nlm.nih.gov/39980423","Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025"
541,"#10228","Skowronski 2024","Skowronski 2024","Influenza","Elder","Medically-attended infection","Case-control","Low",1,70,48,83,"Canada",0,"Sentinel Practitioner Surveillance Network","2023-2024",2023,2024,"Mixed",,,2024,"Euro Surveill",38362622,,"10.2807/1560-7917.Es.2024.29.7.2400076","https://pubmed.ncbi.nlm.nih.gov/38362622","2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)"
544,"#10254","Smolarchuk 2024","Smolarchuk 2024","Influenza","Elder","Medically-attended infection","Case-control","Low",1,57,52,61,"Canada",0,,"2023-2023",2023,2023,"Mixed",,,2024,"Euro Surveill",38214082,,"10.2807/1560-7917.Es.2024.29.2.2300709","https://pubmed.ncbi.nlm.nih.gov/38214082","Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season"
585,"#19530","Whitaker 2024, GB-PC","Whitaker 2024","Influenza","Elder","Medically-attended infection","Case-control","Moderate",1,55,32,70,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
585,"#19530","Whitaker 2024, EN-H","Whitaker 2024","Influenza","Elder","Medically-attended infection","Case-control","Moderate",1,40,29,50,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
585,"#19530","Whitaker 2024, SC-H","Whitaker 2024","Influenza","Elder","Medically-attended infection","Case-control","Moderate",1,53,44,61,"England, Scotland, Wales",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"Influenza Other Respir Viruses",38773753,"PMC11109477","10.1111/irv.13284","https://pmc.ncbi.nlm.nih.gov/articles/PMC11109477","Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom"
618,"#25499","Zhu 2025, B","Zhu 2025","Influenza","Elder","Medically-attended infection","Case-control","Low",1,26,24,29,"US",1,"Population-based","2023-2024",2023,2024,"Mixed",,,2025,"J Infect Dis",40359401,"PMC12353657","10.1093/infdis/jiaf248","https://pmc.ncbi.nlm.nih.gov/articles/PMC12353657","Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season"
102,"#19044","Tenforde 2024","Tenforde 2024","Influenza","Elder","Medically-attended infection","Case-control","Low",1,37,34,40,"US",1,"Multi-center","2023-2024",2023,2024,"IIV",,,2024,"Clin Infect Dis",39656838,"PMC12287760","10.1093/cid/ciae597","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287760","Influenza vaccine effectiveness against hospitalizations and emergency department or urgent care encounters for children, adolescents, and adults during the 2023-2024 season, United States"
166,"#24","AbouChakra 2025","Abou Chakra 2025","Influenza","Elder","Medically-attended infection","Case-control","Low",1,42.01,36.64,46.94,"France",0,"Multi-center","2023-2024",2023,2024,"IIV",,,2025,"Emerg Microbes Infect",40071892,"PMC11980197","10.1080/22221751.2025.2466699","https://pmc.ncbi.nlm.nih.gov/articles/PMC11980197","Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024"
255,"#5595","Costantino 2024","Costantino 2024","Influenza","Elder","Medically-attended infection","Case-control","Low",1,52.7,-38,83.8,"Italy",0,"RespiVirNet network","2023-2024",2023,2024,"IIV",,,2024,"Vaccines",38543939,"PMC10976042","10.3390/vaccines12030305","https://pmc.ncbi.nlm.nih.gov/articles/PMC10976042","Mid-Term Estimates of Influenza Vaccine Effectiveness against the A(H1N1)pdm09 Prevalent Circulating Subtype in the 2023/24 Season: Data from the Sicilian RespiVirNet Surveillance System"
276,"#1107","Emborg 2025","Emborg 2025","Influenza","Elder","Medically-attended infection","Case-control","Low",1,31,17,42,"Denmark",0,"Nationwide","2024-2025",2024,2025,"IIV",,,2025,"Euro Surveill",40156348,,"10.2807/1560-7917.Es.2025.30.12.2500174","https://pubmed.ncbi.nlm.nih.gov/40156348","Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025"
250,"#784","Choi 2025","Choi 2025","Influenza","Elder","Medically-attended infection","Case-control","Moderate",1,13.5,-17.9,36.6,"South Korea",0,"Multi-center","2023-2024",2023,2024,"IIV",,,2025,"Vaccines",40006743,"PMC11861641","10.3390/vaccines13020197","https://pmc.ncbi.nlm.nih.gov/articles/PMC11861641","Early and Late Influenza Vaccine Effectiveness in South Korea During the 20232024 Season"
253,"#21056","Chung 2025","Chung 2025","Influenza","Elder","Medically-attended infection","Case-control","Low",1,37,5,58,"US",1,"Flu VE Network","2023-2024",2023,2024,"IIV",,,2025,"Clin Infect Dis",39761230,"PMC12287938","10.1093/cid/ciae658","https://pmc.ncbi.nlm.nih.gov/articles/PMC12287938","Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season"
617,"#11574","Zhu 2024","Zhu 2024","Influenza","Elder","Medically-attended infection","Case-control","Moderate",1,30,27,33,"US",1,"Multi-center","2023-2024",2023,2024,"IIV",,,2024,"MMWR Morb Mortal Wkly Rep",38421946,"PMC10907038","10.15585/mmwr.mm7308a4","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907038","Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024"
399,"#2089","Lei 2025","Lei 2025","Influenza","Adult/Elder","Medically-attended infection","Case-control","Low",1,75,59,85,"China",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"Hum Vaccin Immunother",39704470,,"10.1080/21645515.2024.2435156","https://pubmed.ncbi.nlm.nih.gov/39704470","Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China"
248,"#5489","Erdwiens 2025","Choi 2024","Influenza","Adult/Elder","Medically-attended infection","Case-control","High",1,35,-31,68,"South Korea",0,"Multi-center","2023-2023",2023,2023,"Mixed",,,2024,"J Korean Med Sci",38651226,"PMC11035711","10.3346/jkms.2024.39.e146","https://pmc.ncbi.nlm.nih.gov/articles/PMC11035711","Interim Estimates of 2023-2024 Seasonal Influenza Vaccine Effectiveness Among Adults in Korea"
295,"#6300","Frutos 2024, Flu VE","Frutos 2024","Influenza","Adult/Elder","Medically-attended infection","Case-control","Low",1,33,16,47,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
295,"#6300","Frutos 2024, VISION","Frutos 2024","Influenza","Adult/Elder","Medically-attended infection","Case-control","Low",1,49,47,51,"US",1,"Multi-center","2023-2024",2023,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",38421935,"PMC10907036","10.15585/mmwr.mm7308a3","https://pmc.ncbi.nlm.nih.gov/articles/PMC10907036","Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States"
615,"#4195","Zhang 2025","Zhang 2025","Influenza","Adult/Elder","Medically-attended infection","Case-control","Moderate",1,49.7,17.7,69.3,"China",0,"Multi-center","2023-2024",2023,2024,"Mixed",,,2025,"Vaccine",39731809,,"10.1016/j.vaccine.2024.126662","https://pubmed.ncbi.nlm.nih.gov/39731809","Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season"
549,"#3602","Sun 2025","Sun 2025","Influenza","Adult/Elder","Medically-attended infection","Case-control","Moderate",1,52.9,7.6,76.8,"China",0,,"2024-2025",2024,2025,"Mixed",,,2025,"Euro Surveill",39980425,,"10.2807/1560-7917.Es.2025.30.7.2500084","https://pubmed.ncbi.nlm.nih.gov/39980425","Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season"
613,"#11414","Zeno 2024","Zeno 2024","Influenza","Adult/Elder","Medically-attended infection","Case-control","Low",1,31,18,42,"South America",0,"REVELAC-i network","2024-2024",2024,2024,"Mixed",,,2024,"MMWR Morb Mortal Wkly Rep",39361525,"PMC11449270","10.15585/mmwr.mm7339a1","https://pmc.ncbi.nlm.nih.gov/articles/PMC11449270","Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024"
